YM BioSciences Announces Presentations for AeroLEF

    YM BIOSCIENCES ANNOUNCES PRESENTATIONS FOR AEROLEF(TM) AT AMERICAN PAIN
SOCIETY ANNUAL MEETING

    MISSISSAUGA, ON, May 5 /CNW/ - YM BioSciences Inc. (AMEX: YMI, TSX: YM,
AIM: YMBA), an oncology company that identifies, develops and commercializes
differentiated products for patients worldwide, today announced that posters
describing research conducted on its pain management product AeroLEF(TM) will
be presented at The 27th Annual Scientific Meeting of the American Pain
Society, which takes place May 8-10, 2008 in Tampa, Florida.
    The first poster presentation, entitled "A randomized controlled trial
demonstrates the efficacy, safety and tolerability of Aerosolized free and
Liposome-Encapsulated Fentanyl (AeroLEF(TM)) via pulmonary administration", is
scheduled to be presented on Thursday, May 8, 2008 (Abstract No.8448, Poster
Board number 265).
    The second poster presentation, entitled "Comparative phase I PK study of
Aerosolized free and Liposome-Encapsulated Fentanyl (AeroLEF(TM)) demonstrates
rapid and extended plasma fentanyl concentrations following inhalation", is
scheduled to be presented on Thursday, May 8, 2008 (Abstract No. 8395, Poster
Board number 243).
    The third poster presentation, entitled "Aerosolized
Liposome-Encapsulated Fentanyl (AeroLEF(TM)) via pulmonary administration
allows patients with moderate to severe post-surgical acute pain to
self-titrate to effective analgesia", is scheduled to be presented on Friday,
May 9, 2008 (Abstract No. 8435, Poster Board number 264).

    About YM BioSciences

    YM BioSciences Inc. is an oncology company that identifies, develops and
commercializes differentiated products for patients worldwide. The Company has
two late-stage products: nimotuzumab, a humanized monoclonal antibody that
targets the epidermal growth factor receptor (EGFR) and is approved in several
countries for treatment of various types of head and neck cancer; and
AeroLEF(TM), a proprietary, inhaled-delivery composition of free and
liposome-encapsulated fentanyl in development for the treatment of moderate to
severe pain, including cancer pain.

    This press release may contain forward-looking statements, which reflect
the Company's current expectation regarding future events. These
forward-looking statements involve risks and uncertainties that may cause
actual results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements. Such factors include, but are not limited to,
changing market conditions, the successful and timely completion of clinical
studies, the establishment of corporate alliances, the impact of competitive
products and pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to time in the
Company's ongoing quarterly and annual reporting. Certain of the assumptions
made in preparing forward-looking statements include but are not limited to
the following: that nimotuzumab will continue to demonstrate a competitive
safety profile in ongoing and future clinical trials; that AeroLEF(TM) will
continue to generate positive efficacy and safety data in future clinical
trials; and that YM and its various partners will complete their respective
clinical trials within the timelines communicated in this release. We
undertake no obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events or
otherwise.

    %SEDAR: 00004652E

/For further information: Thomas Fechtner, the Trout Group LLC, Tel. (646)
378-2931, Email: tfechtner(at)troutgroup.com; James Smith, the Equicom Group
Inc., Tel. [phone] x 229, Email: jsmith(at)equicomgroup.com; Nominated
Adviser, Canaccord Adams Limited, Ryan Gaffney, Tel. [phone]/
(YMBA)




END